Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).

Triple negative breast cancer (TNBC) progresses rapidly but lacks effective targeted therapies. Our previous study showed that downregulating syndecan-binding protein (SDCBP) in TNBC inhibits the proliferation of TNBC cells. Dasatinib is a new small-molecule inhibitor of c-src phosphorylation. The a...

Full description

Bibliographic Details
Main Authors: Xiao-Long Qian, Jun Zhang, Pei-Ze Li, Rong-Gang Lang, Wei-Dong Li, Hui Sun, Fang-Fang Liu, Xiao-Jing Guo, Feng Gu, Li Fu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5283743?pdf=render

Internet

http://europepmc.org/articles/PMC5283743?pdf=render

Similar Items